Leukemia

A CAR-T Cell therapy trial was put on hold by the FDA after the death of three participants.

A recent study identified the optimal time for certain patients with CML to stop TKI treatment.

A phase 3 study showed improved survival rates for patients with high-risk, secondary AML who took Vyxeos.

A recent study showed that for young women who were treated for cancer, the issue of fertility is not adequately addressed.

The FDA expanded the label for Imbruvica for some patients with CLL, as the drug continues to show improved survival benefits.

The FDA granted Blincyto a priority review for certain pediatric patients with ALL.

A recent study showed not only that it is possible to administer chemotherapy in an outpatient setting, but it also can improve patients' quality of life and save money.

The FDA approved Venclexta for patients with CLL who have a 17p deletion and failed at least one prior therapy.

The treatment landscape of chronic lymphocytic leukemia is rapidly evolving, according to Jeffrey Jones, an assistant professor at The Ohio State University Comprehensive Cancer Center.

Kareem Abdul-Jabbar, NBA Legend and chronic myeloid leukemia (CML) survivor, provides advice for newly diagnosed patients with CML.

Patients taking novel treatments for CLL, and their caregivers, should know which side effects to expect — and recognize when they become emergencies.

“You gotta swim, don't let yourself sink. Just find the horizon I promise you, it's not as far as you think.”

A study of acute lymphoblastic leukemia across the age spectrum is showing that some pediatric regimens can be successful in adults.

In the phase 3 RESONATE-2 study, Imbruvica improved progression-free survival (PFS) by 84 percent in previously untreated patients with CLL or SLL.

Why does a cancer diagnosis always come down to being a winner or a loser?

The approval was based on a near doubling in progression-free survival (PFS) seen with the treatment compared with observation in the phase 3 PROLONG trial.

Ed chronicles part II of his chronic lymphocytic leukemia (CLL) story from the third person.

Who could have known that leukemia would transform me from the slow, old guy to the young, fit one?

In an interview with CURE, John C. Byrd discusses the efficacy of acalabrutinib and how it compares with Imbruvica.

I couldn't figure out how to fit in before this post. I read the blogs in the CURE community of contributors and I read the articles on the CURE home page — nothing.

Less than two years after Imbruvica gained approval for patients with CLL, a second-generation agent has demonstrated a 95 percent response rate.

The results showed a two-year overall survival rate of 98 percent with Imbruvica.

CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.

When tyrosine kinase inhibitors benefit patients with CML, can treatment ever be stopped? Experts are looking for an answer.